Pulmonology

These data suggest the promise of morphine for cough among those with idiopathic pulmonary fibrosis, though longer term research may be necessary.

These data indicate that e-cigarettes and nicotine patches were found not to negatively impact pregnant smokers in a significant way, though further study may be valuable.

The first Lungcast of 2024 touches on one of the most pressing issues in medicine: burnout, with an organizational expert.

These data on PMF among coal miners suggest that urgent action may need to be taken to protect these workers from the preventable disease.

Despite these findings, the study highlights the need for a careful decision on the use of lung biopsy in older children given both benefits and risks.

These study results highlight the necessity of raising awareness and implementing public health interventions designed to address respiratory health among this and other populations in early childhood.

A new analysis suggests up to 3 in 10 patients who have an abnormal CT scan experience complications in follow-up procedures.

This research expanded upon existing knowledge from pediatric pulmonary providers regarding wildfire smoke risks and prevention.

Clinicians and investigators alike navigate waning protection against the complex disease to push precedent-setting research and identify new care options.

The data from these meta-analyses highlight the value of developing systems to promote daily toothbrushing among those who have been hospitalized and, particularly, those on mechanical ventilation.

From breakthroughs in disease intervention and vaccines, to global developments in air quality and COVID-19, Lungcast reflects on the people and stories that shaped this year in pulmonology.

During this interview, Perkins described a recent landmark study which yielded some unique findings regarding pathogen-detection.

The Contemporary Pediatrics Editor-in-Chief reviews the pharmacological breakthroughs and epidemiological setbacks that defined RSV in 2023.

Lungcast is joined by an environmental engineer to discuss the burden of harmful air in US school systems today.

These new data highlight key points about the timeline of benefits for those who quit smoking cigarettes, including respiratory and cardiovascular benefits.

This news from the FDA followed a resubmission after the FDA’s complete response letter for the P2X3 receptor antagonist’s use in refractory chronic cough and unexplained cough.

For Lung Cancer Awareness Month, Lungcast speaks with Christy Fischer, a patient who's spent the last 17 years fighting late-stage cancer.

This new data indicates both the high mental health burden on this patient population as well as the usefulness of integrated behavioral health care teams in clinics with a pediatric specialty.

This new data suggests that hospital facilities in the US may need to plan for potentially atypical timing of bronchiolitis season once more for 2023.

This new research sheds light on the importance of follow-up meetings for young patients discharged from emergency departments.

Though primarily observational, this research’s biggest asset is its experimental design and its exploration of viral stimulus-induced bronchial epithelial cell responses from asthmatic donors being treated with tezepelumab.

This newly-developed prediction model evaluating CAP risk was noted as having demonstrated accuracy, strong discriminatory qualities, and practicability in clinical settings.

The marketing denial orders were due to what the FDA stated as insufficient data supporting the products' additional benefit for adults switching from smoking cigarettes to vaping or cessation.

This new data represents the first real-world, US-based data on this drug, demonstrating the efficacy and the safety indications of these clinical trials.

This new data may help clinicians not to over-treat or over-medicalize with infants that have a SARS-CoV-2 infection.